Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration

BACKGROUND: Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the commonly used BRAF inhibitor vemurafenib, affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Maximova, Natalia, Maestro, Alessandra, Zanon, Davide, Marcuzzi, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057420/
https://www.ncbi.nlm.nih.gov/pubmed/32066648
http://dx.doi.org/10.1136/jitc-2019-000388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057420/
https://www.ncbi.nlm.nih.gov/pubmed/32066648
http://dx.doi.org/10.1136/jitc-2019-000388

Ejemplares similares